Pfizer beats by $0.13, beats on revs; raises FY26 EPS and revenue guidance
- Reports Q3 (Sep) earnings of $0.87 per share, excluding non-recurring items, $0.13 better than the FactSet Consensus of $0.74; revenues fell 0.4% year/year to $16.58 bln vs the $15.85 bln FactSet Consensus.
- Eliquis revenue up $513 million, or 25%.
- Padcev revenue up $255 million, or 55%.
- Vyndaqel family (Vyndaqel, Vyndamax, Vynmac) revenue up $193 million, or 12%.
- Co issuesraises guidance for FY26, sees EPS of $2.95-$3.05, excluding non-recurring items, up from prior guidance of $2.80-$3.00. The FactSet Consensus is $2.96. EPS guidance includes a one-time $650 mln acquired In-Process R&D charge related to the in-licensing and collaboration agreement with Innovent Biologics, recorded in Q3 with an unfavorable impact of approximately $0.10. Sees FY26 revs of $62.0-$64.0, up from prior guidance of $60.5-$62.5 bln, vs. $62.24 bln FactSet Consensus.